Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,818.00-1.50%ETH$2,454.88-0.50%GOLD$4,381.40-0.59%OIL$99.30-3.10%
Smart Investors Daily
MA

NASDAQ · MAZE

Maze Therapeutics, Inc.

Healthcare · Biotechnology

$24.82

Up+$0.24 (+0.98%)

Updated Sep 11, 2026, 11:39 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.9B
P/E ratio
-14.34
Dividend yield
0.00%
52-week range
$15.70 – $53.65
Volume
1.18M
Avg. volume
535.35K

Price performance

MAZE price history

1M range · 20 trading sessions · Daily adjusted prices

MAZE closed at $24.82 after 20 trading sessions, down 10.28% for the selected period.

Last close
$24.82
Period change
-10.28%
Period low
$24.58
Period high
$30.42
Daily close
View OHLC price history
MAZE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$24.26$25.62$23.9401$24.821.18M
Sep 9, 2026$25.86$26.545$24.39$24.58401.49K
Sep 8, 2026$25.76$26.57$25.30$26.37365.3K
Sep 4, 2026$25.77$26.49$25.665$26.21273.27K
Sep 3, 2026$26.54$26.96$25.70$25.87477.43K
Sep 2, 2026$26.49$27.44$26.00$26.72440.7K
Sep 1, 2026$26.32$26.66$25.81$26.53326.66K
Aug 31, 2026$27.17$27.20$25.76$26.57493.52K
Aug 28, 2026$28.46$28.46$27.31$27.44250.25K
Aug 27, 2026$28.40$29.01$27.70$28.60692.41K
Aug 26, 2026$30.26$30.40$29.33$29.58230.08K
Aug 25, 2026$29.99$30.80$29.9145$30.42307.67K
Aug 24, 2026$29.27$29.76$28.3339$29.60282.29K
Aug 21, 2026$28.98$29.84$28.98$29.43280.59K
Aug 20, 2026$29.53$29.99$28.46$28.93247.67K
Aug 19, 2026$29.71$30.185$29.11$29.75358.72K
Aug 18, 2026$27.89$29.195$27.00$29.13649.53K
Aug 17, 2026$27.04$28.12$27.00$27.95322.04K
Aug 14, 2026$27.47$27.61$26.85$27.18230.65K
Aug 13, 2026$28.04$28.05$26.9701$27.665383.35K

Latest MAZE news

The latest Smart Investors Daily articles mentioning MAZE.

Stock researchCompany · Overview

MAZE research

Overview

Company profile and research snapshot.

Company profile

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$40.67
Implied upside
—
Analysts
—
MAZE recent ratings
DateFirmRatingTarget
Aug 12, 2026BTIGBuy—
Apr 14, 2026Truist SecuritiesBuy—
Mar 31, 2026JP MorganOverweight—
Mar 25, 2026HC Wainwright & Co.Buy—
Mar 25, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m. ETCiti 2026 Biopharma Back to School Summit; fireside

Benzinga · Aug 11, 2026

Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By